Biomarkers for Renal Disease and Uremic Toxins

2008 ◽  
pp. 435-452
Author(s):  
Eric Schiffer ◽  
Harald Mischak ◽  
Raymond C. Vanholder
Keyword(s):  
Toxins ◽  
2010 ◽  
Vol 2 (10) ◽  
pp. 2340-2358 ◽  
Author(s):  
Nicole Schupp ◽  
August Heidland ◽  
Helga Stopper

2020 ◽  
Vol 43 (7) ◽  
pp. 437-443
Author(s):  
Xiaohong Chen ◽  
Bo Shen ◽  
Xuesen Cao ◽  
Fangfang Xiang ◽  
Jianzhou Zou ◽  
...  

Aims: To investigate the acute effects of hemodiafiltration with endogenous infusion on the elimination of uremic toxins and inflammatory mediators in patients with end-stage renal disease. Materials and methods: A total of 37 end-stage renal disease patients undergoing chronic hemodialysis received a single hemodiafiltration with endogenous infusion dialysis treatment. The acute effects of one hemodiafiltration with endogenous infusion session on uremic toxins and inflammatory mediators were assessed by comparing the pre- and post-hemodiafiltration with endogenous infusion concentrations. Results: Hemoglobin and albumin were stable during hemodiafiltration with endogenous infusion therapy. The mean reduction ratios of β2-microglobulin, p-cresyl sulfate, and indoxyl sulfate were 43.60%, 40.91%, and 43.64%, respectively. Tumor necrosis factor-α also decreased significantly at a mean rate of 28.10%, while the concentrations of interleukin-6 and high-sensitivity C-reactive protein remained unchanged after one session of hemodiafiltration with endogenous infusion. Conclusion: The hemodiafiltration with endogenous infusion system is a new dialysis technique that combines diffusion, convection, and adsorption processes. It allows for extensive solute removal, including protein-bound uremic toxins and some pro-inflammatory cytokines, but does not cause nutrient loss and inflammatory response during the treatment. Although the effect after a single hemodiafiltration with endogenous infusion session is limited, it may be improved by repeated and long-term treatment.


2018 ◽  
Vol 315 (4) ◽  
pp. F890-F902 ◽  
Author(s):  
James G. Atherton ◽  
David S. Hains ◽  
John Bissler ◽  
Bradford D. Pendley ◽  
Ernő Lindner

Current dialysis-dosing calculations provide an incomplete assessment of blood purification. They exclude clearances of protein-bound uremic toxins (PB-UTs), such as polyamines, p-cresol sulfate, and indoxyl sulfate, relying solely on the clearance of urea as a surrogate for all molecules accumulating in patients with end-stage renal disease (ESRD). PB-UTs clear differently in dialysis but also during normal renal function. The kidney clears PB toxins via the process of secretion, whereas it clears urea through filtration. Herein, we review the clearance, accumulation, and toxicity of various UTs. We also suggest possible methods for their monitoring toward the ultimate goal of a more comprehensive dialysis prescription. A more inclusive dialysis prescription would retain the kidney-filtration surrogate, urea, and consider at least one PB toxin as a surrogate for UTs cleared through cellular secretion. A more comprehensive assessment of UTs that includes both secretion and filtration is expected to result in a better understanding of ESRD toxicity and consequently, to reduce ESRD mortality.


Nephrology ◽  
2000 ◽  
Vol 5 (3) ◽  
pp. A93-A93
Author(s):  
Sj Chadban ◽  
P Kerr ◽  
E Briganti ◽  
D Dunstan ◽  
M De Courten ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document